Table 4

Comparison of median PFS and OS reported in the current study with that reported in literature.

AuthornRegionArmsPFS in monthsOS in monthsSecond line
Rosell et al3173EuropeErlotinib 9.719.3NR
Docetaxel or gemcitabine with either cisplatin or carboplatin 5.219.576%
Zhou et al4165ChinaErlotinib13.122.8NR
Gemcitabine with carboplatin 4.627.2NR
Maemondo et al5230JapanGefitinib10.830.567.5%
Paclitaxel/carboplatin 5.423.694.6%
Mitsudomi et al6177JapanGefitinib 9.230.9NR
Docetaxel/cisplatin 6.3NRNR
Sequist et al7345East Asia, Europe, AustraliaAfatinib11.1NRNR
Pemetrexed/cisplatin 6.9NRNR
Current study290IndiaGefitinib 8.41863.8%
Pemetrexed carboplatin followed by pemetrexed maintenance5.622.693.6%
  • *The percentage of patients who received second line among patients who were eligible for same.

  • NR, not reported; OS, overall survival; PFS, progression-free survival.